Manual patch-clamp technique was used to evaluate channel pharmacology using cells transiently transfected with wild-type and V434L mutant channel.
Metrion is working towards the requirements of the FDA’s Comprehensive in vitro Proarrhythmia (CiPA) initiative (cipaproject.org) which comprises 3 parts: 1) High quality in vitro cardiac ion channel assays, 2) Comprehensive in silico action potential (AP) models, and 3) Predictive assays using induced pluripotent stem cell derived cardiomyocytes (iPSC-CM).
We are building upon our panel of in vitro human cardiac ion channel assays and applying the data to various in silico cardiac models, and more recently assessing commercially available iPSC-CM for use in phenotypic assays to assess the pharmacological and risk predictions from our in vitro and in silico cardiac safety data.
Here we outline our progress in validating and implementing all 3 pillars of the CiPA regime by building upon work presented previously at the 2015 SPS meeting in Prague.
Manual patch-clamp technique was used to evaluate channel pharmacology using cells transiently transfected with wild-type and V434L mutant channel.
The HESI Cardiac Safety Committee present results from an international ion channel research study that assessed the variability of hERG data generated using automated patch clamp platforms (QPatch 48, Qube 384 and the SyncroPatch 384i) across four different labs.